Cannara Biotech Inc. LOVE.TO
TSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.10% | 19.85% | 25.10% | 27.58% | 28.40% |
| Total Other Revenue | 139.24% | 17.24% | 100.44% | 190.78% | 1,085.22% |
| Total Revenue | 16.59% | 19.93% | 25.44% | 28.12% | 29.09% |
| Cost of Revenue | 20.52% | 18.76% | 12.20% | 12.69% | 14.54% |
| Gross Profit | 11.71% | 21.55% | 48.67% | 55.07% | 53.23% |
| SG&A Expenses | 33.82% | 31.07% | 18.98% | 14.91% | 17.24% |
| Depreciation & Amortization | 20.59% | 16.87% | 21.85% | 11.60% | 25.03% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.53% | 21.97% | 13.63% | 12.49% | 14.50% |
| Operating Income | -12.99% | 10.14% | 136.39% | 180.14% | 145.57% |
| Income Before Tax | -4.65% | 12.02% | 212.77% | 299.69% | 214.98% |
| Income Tax Expenses | 211.00% | 3,904.30% | 520.31% | 351.28% | -- |
| Earnings from Continuing Operations | -29.13% | -24.41% | 75.55% | 100.52% | 182.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.13% | -24.41% | 75.55% | 100.52% | 182.88% |
| EBIT | -12.99% | 10.14% | 136.39% | 180.14% | 145.57% |
| EBITDA | -7.94% | 6.98% | 81.19% | 101.29% | 87.84% |
| EPS Basic | -32.90% | -26.35% | 72.80% | 98.46% | 188.97% |
| Normalized Basic EPS | -9.81% | 30.02% | 457.93% | 772.73% | 468.71% |
| EPS Diluted | -33.51% | -31.74% | 75.69% | 118.24% | 223.33% |
| Normalized Diluted EPS | -10.45% | 29.41% | 466.43% | 793.68% | 463.70% |
| Average Basic Shares Outstanding | 5.04% | 3.42% | 1.96% | 0.88% | -0.24% |
| Average Diluted Shares Outstanding | 5.58% | 3.74% | 2.68% | 1.58% | 0.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |